



PRESS RELEASE

Nobel Biocare Holding AG holds 94.6 per cent of Nobel Biocare AB and completes the public offer

The public offer by Nobel Biocare Holding AG to acquire all the outstanding shares in Nobel Biocare AB has been accepted to such an extent that Nobel Biocare Holding AG now controls approximately 94.6 per cent of the shares and votes in Nobel Biocare AB.

All the conditions for Nobel Biocare Holding AG's public offer as stated in the offer document dated 27 May 2002 have therefore been met and Nobel Biocare Holding AG will subsequently complete the public offer.

Settlement for those who have accepted the offer up to and including 18 June 2002 will commence on 21 June 2002. Trading of the new shares in Nobel Biocare Holding AG on the SWX Swiss Exchange and on the Stockholm Stock Exchange will commence on 24 June 2002.

In order to provide the remaining shareholders of Nobel Biocare AB who have not tendered their shares during the acceptance period up until 18 June 2002 a further opportunity to tender their shares, Nobel Biocare Holding AG has decided to extend the acceptance period for these shareholders up to and including 9 July 2002. Settlement for those shareholders who will tender their shares during the extended acceptance period up to and including 9 July 2002 is expected to commence on 12 July 2002.

Nobel Biocare Holding AG intends to request that the board of Nobel Biocare AB initiates a delisting of Nobel Biocare AB's shares from the Stockholm Stock Exchange (Stockholmsbörsen) as soon as possible after 9 July 2002.

Gothenburg, 20 June 2002

Nobel Biocare Holding AG

For further information:

Harrieth Sundaeus, Chief Financial Officer, Nobel Biocare AB, tel. +46 31 81 88 48,
mobile +46 708 81 88 48

Michaela Ahlberg, Legal Counsel, Nobel Biocare AB, tel. +46 31 81 88 29,
mobile +46 31 81 88 29.

Copies of this press release are not being, and must not be, mailed or otherwise distributed or sent in or into Australia or Japan. The Offer will and is not to be made in these countries.
Statements made in this press release that relate to future events, performance or financial results of Nobel Biocare are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. Nobel Biocare undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these

forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in Nobel Biocare's annual reports and in the Offer Document dated 27 May 2002.

Nobel Biocare is an innovative, medical devices company, whose core business comprises dental implants and dental prosthetics. The company's product systems for dental implants, Brånemark System® and Replace™, are world leaders and have a global market share of around 38%.

The company's other product line, Procera®, is a unique, IT-based process for the industrial production of dental prosthetics. The system has been launched very successfully in more than 35 countries in North America, Europe, South East Asia and South America.

Nobel Biocare has around 1,300 employees and, in 2001 net sales totaled SEK 2 663 million. The company's headquarters are located in Gothenburg, Sweden, while production takes place in Sweden and the USA. Nobel Biocare has its own sales companies in 26 countries.

**Nobel Biocare AB, Box 5190, S-402 26 Göteborg, Sweden,
tel +46 31-81 88 00, fax +46 31-16 31 52.**

investor.relations@nobelbiocare.se

www.nobelbiocare.com